A CoCR13 carbonyl reductase mutant with enhanced acid resistance and its application in a citrate buffer system
By mutating the CoCR13 carbonyl reductase gene and introducing specific amino acid substitutions, the problem of insufficient activity under acidic conditions in the citrate buffer system was solved, achieving high enzyme activity and high catalytic efficiency under acidic conditions.
Patent Information
- Application Number
- CN202611618762.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-20
- Publication Date
- 2026-11-17
AI Technical Summary
The existing CoCR13 carbonyl reductase has insufficient activity retention under acidic conditions in a citrate buffer system, which affects its application in scenarios with decreased pH.
By mutating the CoCR13 carbonyl reductase gene and introducing specific amino acid substitutions (such as S163D or D74E, A144D, S163D, N204D, S264E), its stability and catalytic activity under acidic conditions can be improved.
The mutant maintained a high enzyme activity under acidic conditions, improved catalytic efficiency, and significantly enhanced catalytic performance in the citric acid buffer system.
Smart Images

Figure CN123107945A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the fields of genetic engineering and enzyme engineering technology, specifically relating to a CoCR13 carbonyl reductase mutant with improved acid resistance, the nucleic acid molecule encoding the mutant, the recombinant expression vector, the recombinant host cell, the method for preparing the mutant, and its application in the catalytic preparation of bosine in a citrate buffer system. Background Technology
[0002] Bosein is a C - Glycoside derivatives, which can be derived from 1- C -(β-D-xylanosyl)-acetone is prepared via carbonyl reduction. When using chemical reducing agents such as sodium borohydride for carbonyl reduction, inorganic boron byproducts may be generated, and post-processing issues may arise. However, using NADPH (reduced nicotinamide adenine dinucleotide phosphate, hereinafter referred to as NADPH) as a coenzyme and employing carbonyl reductase to catalyze the reduction reaction allows for carbonyl conversion under relatively mild conditions, thus providing an alternative route for the biocatalytic preparation of bosine.
[0003] The applicant's laboratory currently possesses a parental CoCR13 carbonyl reductase capable of catalyzing 1- C The reduction reaction of β-D-xylanosyl)-acetone. However, existing catalytic systems typically use phosphate buffers, which introduce phosphate ions into the reaction system and increase the phosphorus load in subsequent wastewater. Replacing phosphate buffer with citrate buffer avoids the introduction of phosphate ions from the buffer. However, this alternative requires the carbonyl reductase used to be adaptable to the citrate buffer system and to maintain catalytic activity and stability when the system pH decreases.
[0004] Meanwhile, CoCR13 carbonyl reductase catalyzes 1- C The reduction of β-D-xylanosyl)-acetone is NADPH-dependent. Glucose dehydrogenase is commonly used in the NADPH coenzyme cycle to reduce NADP-... + The enzyme is reduced to NADPH, while simultaneously oxidizing glucose to form gluconic acid, thereby lowering the pH of the reaction system. Therefore, when employing this coenzyme cycle, CoCR13 carbonyl reductase must also maintain good activity under acidic conditions.
[0005] However, the parental CoCR13 carbonyl reductase exhibits limited activity retention after incubation under acidic conditions. Following the method described in Example 3 of this specification, after incubation at 30°C for 0.5 h in 100 mM citrate buffer (pH 3.0) at 30°C, the remaining enzyme activity was only 7.45% ± 0.08%; after incubation at 30°C for 6 h in 100 mM citrate buffer (pH 4.0) at 30°C, the remaining enzyme activity was 15.63% ± 1.08%; and after incubation at 30°C for 6 h in 100 mM citrate buffer (pH 5.0) at 30°C, the remaining enzyme activity was 61.97% ± 2.44%. This decrease in activity limits the application of the parental enzyme in citrate buffer systems or in scenarios where the pH is lowered during the reaction.
[0006] Therefore, it is necessary to obtain a CoCR13 carbonyl reductase mutant that retains the carbonyl reduction catalytic function while exhibiting a high residual enzyme activity after incubation under acidic conditions, in order to address the problem of insufficient activity retention of the parent enzyme in citrate buffer systems and when pH decreases due to the NADPH coenzyme cycle. Summary of the Invention
[0007] To address the above-mentioned technical problems, this invention proposes a CoCR13 carbonyl reductase mutant with improved acid resistance and its application in a citrate buffer system. This mutant retains its carbonyl reduction catalytic function while exhibiting high residual enzyme activity after incubation under acidic conditions, and can be used to catalyze 1-… C -(β-D-xylanosyl)-acetone is reduced to produce bosine.
[0008] This invention uses the CoCR13 carbonyl reductase shown in SEQ ID NO:1 as the parent enzyme, and introduces S163D substitution, or a combination of D74E, A144D, S163D, N204D, and S264E substitution, to obtain the mutants shown in SEQ ID NO:3 and SEQ ID NO:5, respectively. Measurements were performed according to the methods described in Examples 2 and 3, and the specific activity and residual enzyme activity after incubation under the acidic conditions of both mutants were higher than those of the parent enzyme.
[0009] Specifically, in a first aspect, the present invention provides a CoCR13 carbonyl reductase mutant, which is obtained by mutating serine S at position 163 of the parental sequence to aspartic acid D, using the amino acid sequence shown in SEQ ID NO:1 as the parental sequence. The amino acid sequence of the mutant is shown in SEQ ID NO:3. Alternatively, the mutant can be obtained by mutating aspartic acid D at position 74 to glutamic acid E, alanine A at position 144 to aspartic acid D, serine S at position 163 to aspartic acid D, asparagine N at position 204 to aspartic acid D, and serine S at position 264 to glutamic acid E. The amino acid sequence of the mutant is shown in SEQ ID NO:5. The mutant is able to catalyze 1- in the presence of NADPH. C -(β-D-xylanosyl)-acetone undergoes a reduction reaction to produce bosenoin.
[0010] Under the conditions described in Example 3, the CoCR13 carbonyl reductase mutant shown in SEQ ID NO:3 was incubated in 100 mM, pH 3.0 citrate buffer at 30°C for 0.5 h, and its residual enzyme activity was not less than 14%; after incubating in 100 mM, pH 4.0 citrate buffer at 30°C for 6 h, its residual enzyme activity was not less than 38%; and after incubating in 100 mM, pH 5.0 citrate buffer at 30°C for 6 h, its residual enzyme activity was not less than 92%.
[0011] Under the conditions described in Example 3, the CoCR13 carbonyl reductase mutant shown in SEQ ID NO:5 was incubated in 100 mM, pH 3.0 citrate buffer at 30°C for 0.5 h, and its residual enzyme activity was not less than 20%; after incubating in 100 mM, pH 4.0 citrate buffer at 30°C for 6 h, its residual enzyme activity was not less than 32%; and after incubating in 100 mM, pH 5.0 citrate buffer at 30°C for 6 h, its residual enzyme activity was not less than 89%.
[0012] The remaining enzyme activity was determined according to the unified activity assay method described in Examples 2 and 3: Samples were taken after incubation under acidic conditions, and the enzyme was incubated in 100 mM citrate buffer at pH 6.0 with NADPH as a coenzyme for 1- C Using β-D-xylanosyl)-acetone as a substrate, enzyme activity was determined at 30°C, and the initial enzyme activity of the same enzyme sample that had not been incubated under the corresponding acidic conditions was taken as 100%.
[0013] In a second aspect, the present invention provides a nucleic acid molecule that encodes a CoCR13 carbonyl reductase mutant of the first aspect.
[0014] Furthermore, the nucleotide sequences of the above-mentioned nucleic acid molecules are shown in SEQ ID NO:4 or SEQ ID NO:6.
[0015] In a third aspect, the present invention provides a recombinant expression vector containing the nucleic acid molecule of the second aspect of the present invention.
[0016] Furthermore, the recombinant expression vector is the pET-28a(+) vector.
[0017] In a fourth aspect, the present invention provides a recombinant host cell comprising the recombinant expression vector of the third aspect of the present invention.
[0018] Furthermore, the recombinant host cell is Escherichia coli C43(DE3).
[0019] In a fifth aspect, the present invention provides a method for preparing the CoCR13 carbonyl reductase mutant described in the first aspect of the present invention, comprising the following steps: culturing the recombinant host cell described in the fourth aspect of the present invention and inducing protein expression to obtain the CoCR13 carbonyl reductase mutant described in the first aspect of the present invention.
[0020] In a sixth aspect, the present invention provides a catalyst 1- C The method for preparing Bosein by reduction of β-D-xylanosyl)-acetone includes the following steps: In a reaction system composed of citrate buffer, using the CoCR13 carbonyl reductase mutant described in the first aspect of this invention as a catalyst, in the presence of NADPH, the substrate 1- C -(β-D-xylanosyl)-acetone undergoes a reduction reaction to produce bosine.
[0021] Preferably, the citrate buffer used to prepare the reaction system has a concentration of 100 mM and a pH of 6.0.
[0022] Preferably, in the reaction system 1- C -(β-D-xylanosyl)-acetone final concentration 20 mM, NADPH final concentration 0.47 mM.
[0023] Preferably, the reduction reaction temperature is 30°C.
[0024] A seventh aspect of the present invention provides the use of the CoCR13 carbonyl reductase mutant described in the first aspect of the present invention in the preparation of bosonicine, said use comprising catalyzing 1- C Reduction reaction of β-D-xylanyl)-acetone.
[0025] The beneficial effects of this invention are as follows: (1) Compared with the parental CoCR13 carbonyl reductase shown in SEQ ID NO:1, both mutants of the present invention maintain the 1- CThe α-(β-D-xylopyranosyl)-acetone exhibits carbonyl reduction catalytic activity and shows enhanced specific activity under the detection conditions of this application. The specific activity of the S163D mutant shown in SEQ ID NO:3 is 14.79 U / mg, approximately 1.60 times that of the parent enzyme; the specific activity of the five-point mutant shown in SEQ ID NO:5 is 20.89 U / mg, approximately 2.26 times that of the parent enzyme.
[0026] (2) Regarding acid stability, the residual enzyme activity of the S163D mutant after incubation at pH 3.0 for 0.5 h and at pH 4.0 for 6 h was 14.05% ± 0.72% and 38.97% ± 0.81%, respectively, which were approximately 1.89 times and 2.49 times the corresponding values of the parent enzyme, respectively. The residual enzyme activity of the five-point mutant under the same conditions was 20.38% ± 2.20% and 32.4% ± 1.2%, respectively, which were approximately 2.74 times and 2.07 times the corresponding values of the parent enzyme, respectively. This indicates that the activity retention capacity of both mutants after incubation under the aforementioned acidic conditions was higher than that of the parent enzyme.
[0027] (3) Under the measurement conditions described in this specification, the catalytic efficiency (kcat / ) of the five-point mutant K m The value was 2.19 mM. -1 s -1 It is approximately 2.08 times that of the parent enzyme. All the above results are based on the experimental conditions and data in the table described in this instruction manual. Attached Figure Description
[0028] Figure 1 For carbonyl reductase mutants to catalyze 1- C Schematic diagram of the reaction principle for the synthesis of bosenoside from β-D-xylanopyranosyl)-acetone; Figure 2 A schematic diagram of the process for preparing bosine by catalyzing the reduction of the ketone substrate in a citrate buffer system using the CoCR13 carbonyl reductase mutant. Detailed Implementation
[0029] To enable those skilled in the art to better understand the present invention, it will now be further described in conjunction with specific embodiments. Unless otherwise stated, all reagents and materials used are commercially available, and the molecular biology operations employed can be performed according to conventional methods in the art.
[0030] In this invention, amino acid substitutions are represented using the format "original amino acid single-letter code - site number - substitute amino acid single-letter code". For example, S163D indicates that serine at position 163 of the parental sequence is replaced by aspartic acid.
[0031] The term "parental CoCR13 carbonyl reductase" as used in this invention refers to a protein composed of 334 amino acids as shown in SEQ ID NO:1, and is not described as a wild-type protein relative to a database reference sequence.
[0032] The term "residual enzyme activity" in this invention refers to the ratio of enzyme activity after incubation under acidic conditions to the initial enzyme activity of the same enzyme sample before incubation, expressed as a percentage. Unless otherwise stated, enzyme activity is determined according to the method described in Example 2. The improved acid tolerance described in this invention is evaluated by measuring the residual enzyme activity under uniform activity testing conditions after incubation under acidic conditions.
[0033] Example 1 The construction, expression, and acquisition of the CoCR13 carbonyl reductase mutant include the following steps: 1. Parental sequences and mutant design SEQ ID NO:1 is the amino acid sequence of the parental CoCR13 carbonyl reductase used in this embodiment, consisting of 334 amino acids.
[0034] SEQ ID NO:2 is the nucleotide sequence encoding the parent enzyme shown in SEQ ID NO:1, consisting of 1005 nucleotides, with a stop codon TAA at the end, and a coding region of 1002 nucleotides without the stop codon.
[0035] By introducing S163D substitutions into the parental sequence shown in SEQ ID NO:1, an S163D mutant with an amino acid sequence as shown in SEQ ID NO:3 was obtained, and its encoding nucleotide sequence is shown in SEQ ID NO:4.
[0036] Based on the parental sequence shown in SEQ ID NO:1, D74E, A144D, S163D, N204D and S264E substitutions were introduced simultaneously to obtain a five-point mutant with an amino acid sequence as shown in SEQ ID NO:5, and its encoding nucleotide sequence is shown in SEQ ID NO:6.
[0037] 2. Site-directed mutagenesis and expression vector construction Using the pET-28a(+) plasmid containing the gene encoding CoCR13 from the parent shown in SEQ ID NO:2, which was already available in the laboratory, as a template, forward and reverse primers containing the corresponding mutant bases were designed based on the target mutation site. The primer sequences used are listed below in the 5′ to 3′ direction: Table 1 Primer sequences for mutation sites The whole plasmid was amplified by PCR. The 25 μL PCR reaction system included: 12.5 μL Phanta Max Super-Fidelity DNA Polymerase, 1 μL template plasmid, 1 μL 10 μM upstream primer, 1 μL 10 μM downstream primer, and 9.5 μL ddH2O.
[0038] The PCR program was as follows: 98℃ pre-denaturation for 30 s; 98℃ denaturation for 10 s, 55℃ annealing for 5 s, and 72℃ extension for 40 s, for a total of 30 cycles; 72℃ extension for 5 min; cooling to 4℃. After PCR, DpnI restriction endonuclease was added, and the mixture was digested at 37℃ for 2 h to remove methylated parental template plasmids.
[0039] Add 5 μL of the digestion product to the thawed E. coli DH5α competent cells, incubate on ice for 30 min, heat shock at 42°C for 45 s, and incubate on ice for 3 min. Add 900 μL of sterile LB liquid medium and incubate at 37°C and 200 rpm for 1 h. Then centrifuge at 8000 rpm for 45 s, discard approximately 900 μL of supernatant, resuspend the cells in the remaining liquid, and spread them on LB solid medium containing 50 μg / mL kanamycin. Incubate overnight at 37°C with the medium inverted.
[0040] Single colonies were picked and inoculated into LB liquid medium containing 50 μg / mL kanamycin and incubated overnight at 37°C and 200 rpm. Plasmid sequencing was performed on the culture to confirm the target mutation. Sterile glycerol was added to the confirmed bacterial culture to a final volume fraction of 20%, and the culture was stored at -80°C.
[0041] 3. Heterologous expression of mutants The sequenced pET-28a(+) recombinant plasmid was transformed into *E. coli* C43(DE3) competent cells. The competent cells were thawed on ice, 1 μL of the recombinant plasmid was added, and the cells were incubated on ice for 30 min, heat-shocked at 42°C for 45 s, and then incubated on ice for 3 min. 900 μL of sterile LB broth was added, and the cells were incubated at 37°C and 200 rpm for 1 h. 100 μL of the bacterial culture was then spread onto LB solid medium containing 50 μg / mL kanamycin and incubated upside down at 37°C overnight.
[0042] Single colonies were picked and inoculated into LB liquid medium containing 50 μg / mL kanamycin, and incubated overnight at 37°C and 200 rpm. Seed culture was inoculated into 50 mL of LB liquid medium containing 50 μg / mL kanamycin at a 1% inoculation rate, and incubated at 37°C and 200 rpm until OD500 reached. 600The concentration was 0.6-0.8; IPTG was added to a final concentration of 0.1 mM, and the cells were induced and cultured at 28℃ and 200 rpm for 6 h; the cells were collected by centrifugation at 8000 rpm for 8 min.
[0043] Using a 6×His tag encoded by the pET-28a(+) vector, purified enzyme solution was obtained for the following assays using the conventional nickel ion affinity purification method for histidine-tagged proteins.
[0044] The composition of LB liquid medium is as follows: each 1 L of medium contains 10 g of tryptone, 5 g of yeast extract, and 10 g of NaCl, with a pH of 7.0-7.2, and is sterilized at 121°C for 20 min. When preparing LB solid medium, add 1.8 g of agar powder per 100 mL of liquid medium.
[0045] Example 2 Determination of enzyme activity and kinetic parameters of CoCR13 carbonyl reductase mutant CoCR13 carbonyl reductase mutant catalyzes 1- C The reaction principle of -(β-D-xylanopyranosyl)-acetone reduction to Bosein is as follows: Figure 1 As shown.
[0046] The enzyme activities of parental CoCR13 carbonyl reductase and various mutants were determined using the NADPH consumption method. The total volume of the enzyme activity assay system was 200 μL, including 150 μL of citrate buffer (prepared to a concentration of 100 mM, pH 6.0), 10 μL of NADPH solution (final concentration in the reaction system was 0.47 mM), and 20 μL of 1- C -(β-D-xylanosyl)-acetone solution (final concentration in the reaction system is 20 mM) and 20 μL of purified enzyme solution.
[0047] The above reaction system was mixed and added to a 96-well plate. The absorbance at 340 nm was continuously monitored over 8 minutes at 30°C using a microplate reader. The rate of absorbance decrease was calculated from the linear segment of the absorbance change over time. The amount of NADPH consumed per unit time was calculated based on the NADPH standard curve, and the enzyme activity was calculated accordingly.
[0048] One unit of enzyme activity (U) is defined as the amount of enzyme required to catalyze the consumption of 1 μmol of NADPH per minute under the above-described assay conditions. Specific activity is expressed in U / mg.
[0049] Under the same detection conditions, the specific activity, transformation number (kcat), and Michaelis constant of the parent enzyme and two mutants were obtained. K m ) and catalytic efficiency (kcat / K mThe results are shown in Table 2. Each experiment had at least three parallel samples, and the results are expressed as mean ± standard deviation.
[0050] Table 2. Specific activity and kinetic parameters of the initial carbonyl reductase and mutants. As shown in Table 2, under the above detection conditions, the specific activities of the S163D mutant and the five-point mutant were approximately 1.60 times and 2.26 times that of the parent enzyme, respectively; the catalytic efficiency of the five-point mutant was approximately 2.08 times that of the parent enzyme.
[0051] Example 3 Acid stability assay of CoCR13 carbonyl reductase mutant The purified parental CoCR13 carbonyl reductase, S163D mutant, and five-point mutant enzyme solutions were placed in 100 mM citrate buffer at pH 3.0, pH 4.0, and pH 5.0, respectively, and incubated at 30°C for 0.5 h, 6 h, and 6 h, respectively. That is, the pH 3.0 group was incubated for 0.5 h, the pH 4.0 group for 6 h, and the pH 5.0 group for 6 h. After incubation in each group, equal volumes of enzyme solution were taken, adjusted to the same activity assay conditions, and the enzyme activity was measured according to the enzyme activity assay method described in Example 2.
[0052] Taking the initial enzyme activity of the same enzyme sample that has not been incubated under the appropriate acidic conditions as 100%, the remaining enzyme activity is calculated according to the following formula: Remaining enzyme activity (%) = Enzyme activity after incubation under acidic conditions ÷ Initial enzyme activity before incubation × 100%.
[0053] Each experiment had at least three parallel samples, and the results were expressed as mean ± standard deviation, as shown in Table 3.
[0054] Table 3. Residual enzyme activity of parental CoCR13 carbonyl reductase and mutant after incubation under acidic conditions. This invention validated the specific activities of carbonyl reductases with other amino acid sequences and mutants obtained using the method of this invention. Table 3 shows that, under the above detection conditions, the residual enzyme activity of both mutants after incubation in citrate buffer at pH 3.0, pH 4.0, and pH 5.0 was higher than that of the parent CoCR13 carbonyl reductase. The mutant with the highest catalytic efficiency was 2.08 times that of the initial carbonyl reductase.
[0055] The above description is merely a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and inventive concept of the present invention, should be covered within the scope of protection of the present invention.
[0056] Sequence Description SEQ ID NO:1 is the amino acid sequence of the parent CoCR13 carbonyl reductase, consisting of 334 amino acids.
[0057] SEQ ID NO:2 is the nucleotide sequence encoding the parent enzyme shown in SEQ ID NO:1, consisting of 1005 nucleotides and including the terminal stop codon TAA.
[0058] SEQ ID NO:3 is the amino acid sequence of the CoCR13 carbonyl reductase mutant containing the newly added amino acid substitution of S163D, with a total of 334 amino acids.
[0059] SEQ ID NO:4 is the nucleotide sequence encoding the mutant shown in SEQ ID NO:3, consisting of 1005 nucleotides and including the terminal stop codon TAA.
[0060] SEQ ID NO:5 is the amino acid sequence of a CoCR13 carbonyl reductase mutant containing five newly substituted amino acids: D74E, A144D, S163D, N204D, and S264E, totaling 334 amino acids.
[0061] SEQ ID NO:6 is the nucleotide sequence encoding the mutant shown in SEQ ID NO:5, consisting of 1005 nucleotides and including the terminal stop codon TAA.
[0062] SEQ ID NO:1 MPVFISGATGFIAQHVIKELLNDGFQVIGSVRSKAKGEYLSSLIKSKKFSYAVVPDIVATGAFDQVLQENQDIDSFIHTASPVDFQVSDVQTGLLDPAIEGTKNVLIAIEKYGKNVVVVTSSTSAVEDSGSRPSNSLLTEASWNEITLEQGLKSARLGYSAAKTFAEKEVWKFAAEHNGTFNITTVNPTYVFGPQAFEVQNKSQLNFSAEYVNNIFKLKPNDDIPMFVGLFIDVRDVAKAHVAAIKKPKEFNGQRLVLINSAWTNELLAVIINKHFPNVDIPKGNIEKSDEELKKADLKWDNSKTKKLLGYSFIPIEKSVVDAVQQLLDTE SEQ ID NO:2 SEQ ID NO:3 MPVFISGATGFIAQHVIKELLNDGFQVIGSVRSKAKGEYLSSLIKSKKFSYAVVPDIVATGAFDQVLQENQDIDSFIHTASPVDFQVSDVQTGLLDPAIEGTKNVLIAIEKYGKNVVVVTSSTSAVEDSGSRPSNSLLTEASWNEITLEQGLKSARLGYDAAKTFAEKEVWKFAAEHNGTFNITTVNPTYVFGPQAFEVQNKSQLNFSAEYVNNIFKLKPNDDIPMFVGLFIDVRDVAKAHVAAIKKPKEFNGQRLVLINSAWTNELLAVIINKHFPNVDIPKGNIEKSDEELKKADLKWDNSKTKKLLGYSFIPIEKSVVDAVQQLLDTE SEQ ID NO:4 SEQ ID NO:5 MPVFISGATGFIAQHVIKELLNDGFQVIGSVRSKAKGEYLSSLIKSKKFSYAVVPDIVATGAFDQVLQENQDIESFIHTASPVDFQVSDVQTGLLDPAIEGTKNVLIAIEKYGKNVVVVTSSTSAVEDSGSRPSNSLLTEDSWNEITLEQGLKSARLGYDAAKTFAEKEVWKFAAEHNGTFNITTVNPTYVFGPQAFEVQDKSQLNFSAEYVNNIFKLKPNDDIPMFVGLFIDVRDVAKAHVAAIKKPKEFNGQRLVLINEAWTNELLAVIINKHFPNVDIPKGNIEKSDEELKKADLKWDNSKTKKLLGYSFIPIEKSVVDAVQQLLDTE SEQ ID NO:6
Claims
1. A CoCR13 carbonyl reductase mutant, characterized in that, Using the amino acid sequence shown in SEQ ID NO:1 as the parental sequence, the 163rd serine S of the parental sequence was mutated to aspartic acid D to obtain the mutant, and the amino acid sequence of the mutant is shown in SEQ ID NO:
3. Alternatively, the mutant can be obtained by mutating aspartic acid D at position 74 of the parental sequence to glutamic acid E, alanine A at position 144 to aspartic acid D, serine S at position 163 to aspartic acid D, asparagine N at position 204 to aspartic acid D, and serine S at position 264 to glutamic acid E. The amino acid sequence of the mutant is shown in SEQ ID NO:
5.
2. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the CoCR13 carbonyl reductase mutant of claim 1.
3. The nucleic acid molecule according to claim 2, characterized in that, The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:4 or SEQ ID NO:
6.
4. A recombinant expression vector, characterized in that, The recombinant expression vector contains the nucleic acid molecule as described in claim 2 or 3.
5. The recombinant expression vector according to claim 4, characterized in that, The recombinant expression vector is the pET-28a(+) vector.
6. A recombinant host cell, characterized in that, The recombinant host cell comprises the recombinant expression vector as described in claim 4 or 5.
7. The recombinant host cell according to claim 6, characterized in that, The recombinant host cell was Escherichia coli C43(DE3).
8. A method for preparing the CoCR13 carbonyl reductase mutant according to claim 1, characterized in that, The method includes the following steps: culturing the recombinant host cell as described in claim 6 or 7 and inducing protein expression to obtain the CoCR13 carbonyl reductase mutant as described in claim 1.
9. A catalyst 1- C A method for preparing Bosein by reduction of β-D-xylanosyl)-acetone, characterized in that... The process includes the following steps: In a reaction system composed of citrate buffer, using the CoCR13 carbonyl reductase mutant of claim 1 as a catalyst, in the presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH), catalyzing substrate 1- C -(β-D-xylanosyl)-acetone undergoes a reduction reaction to produce bosine.
10. The catalyst 1- according to claim 9 C A method for preparing Bosein by reduction of β-D-xylanosyl)-acetone, characterized in that... The citrate buffer solution has a concentration of 100 mM and a pH of 6.
0.
11. The catalyst 1- according to claim 9 C A method for preparing Bosein by reduction of β-D-xylanosyl)-acetone, characterized in that... In the reaction system 1- C -(β-D-xylanosyl)-acetone final concentration 20 mM, reduced nicotinamide adenine dinucleotide phosphate (NADPH) final concentration 0.47 mM.
12. The catalyst 1- according to claim 9 C A method for preparing Bosein by reduction of β-D-xylanosyl)-acetone, characterized in that... The reduction reaction temperature is 30℃.
13. The application of the CoCR13 carbonyl reductase mutant according to claim 1 in the preparation of Bosein, characterized in that, The application includes using the CoCR13 carbonyl reductase mutant to catalyze 1- C Reduction reaction of β-D-xylanyl)-acetone.
